

WEIGHT-BAND DOSING TABLES: SIMPLIFYING PAEDIATRIC ART

James J C Nuttall, MB ChB, DTM&H

Paediatric Infectious Diseases Unit, Red Cross Children's Hospital and University of Cape Town

One of the obstacles to scaling up paediatric antiretroviral therapy (ART) coverage in resource-limited settings is the relative complexity of paediatric dosing. There is a need to simplify ART in order to facilitate treatment initiation and ongoing management of infants and children by health care providers, as well as to support adherence in the home. This article reviews the development of weight-band dosing tables as a strategy for simplifying the delivery of paediatric ART.

In 2007, only 8% of the estimated 1 800 000 children (0 - 14 years) living with HIV in sub-Saharan Africa were receiving antiretroviral therapy (ART). Coverage will need to be expanded greatly if the goal of providing ART to 80% of children in need by 2010 is to be met.¹ Moreover, recent evidence highlights early initiation of ART as particularly critical for infants with HIV.² Clinical guidelines issued by the World Health Organization (WHO) now recommend immediate initiation of ART for all HIV-infected infants.³

Paediatric ART management involves a complex process of interactions between patients, families, health care providers and the antiretrovirals (ARVs) themselves. Barriers to the delivery of effective treatment occur both within the health care system and in the home. These include delayed diagnosis, limited availability of health care providers trained in paediatric ART, few available paediatric ARV formulations, complicated regimens and dosing schedules, and poor palatability of some ARVs. Difficulties in the home include overcrowding, difficult work schedules of the parents and the stresses associated with parental disclosure in the home. Unlike adults, children require changes in antiretroviral dose as they grow and become older, and rely upon adult caregivers to administer medicines.⁴

Children have traditionally been dosed according to body surface area (BSA) (e.g. zidovudine (AZT), didanosine (ddI), lopinavir/ritonavir (LPV/r)), weight (mg/kg) (e.g. stavudine (d4T), lamivudine (3TC), abacavir (ABC), nevirapine (NVP)) or dose per weight band (efavirenz (EFV)). Manufacturers' recommendations for some ARV drugs (e.g. LPV/r) include both BSA and weight-based dosing methods.⁵ The calculation of BSA generally requires accurate measurement of the child's weight and length or height (ideally with a stadiometer or measuring box), and a normogram or mathematical formula (e.g. Mosteller formula).⁶ For both BSA and mg/kg

weight-based dosing approaches, the calculated dose of each ARV drug must be rounded up or down as a 'best-fit' dosage according to which solid or liquid formulations of the ARV drug are available. This may lead to confusion and uncertainty on the part of the prescriber.

In resource-limited settings (RLS), primary care doctors and nurses rather than paediatricians are responsible for the majority of paediatric ART initiation and follow-up. Lack of accurate measuring equipment and the relative complexity of BSA dosing may inhibit initiation of ART in infants and young children or mean that inappropriate doses are given. While the most 'accurate' dosing may be obtained with the use of liquid formulations, large volumes of solutions (which may require refrigeration, e.g. d4T solution) may be challenging for caregivers to administer to young children, particularly if palatability is poor (e.g. LPV/r).

ART simplification strategies are required to help health care providers manage ART in children, and to help caregivers and children adhere to therapy. Interventions include the use of adult or preferably paediatric fixed-dose combinations (FDCs), selection of doses based on weight band rather than individual mg/kg or BSA doses, prescription of pills or capsules rather than liquids, and identification of reliable once-daily regimens.

MOVING FROM BSA AND WEIGHT-BASED DOSING APPROACHES TO WEIGHT-BAND DOSAGE TABLES

Weight-band dosage tables assist health care providers by assigning a fixed dose of medication for a particular weight range (e.g. 1.5 ml of LPV/r solution for children weighing 4 - 9.9 kg, or half a 150 mg 3TC tablet for children weighing 14 - 19.9 kg). In large public sector

treatment programmes, tables can reduce the time and risk of dosing errors involved in calculating multiple ARV doses by weight or BSA. They can also facilitate easier checking of doses against weight gain by clinicians, nurses, pharmacists or adherence counsellors. Under-dosing of ARVs, due in part to a lack of regular dose adjustments for ongoing growth, has been described in a large cohort of children in the UK and Ireland.⁷ A study in Thailand found that 17 of 18 doctors using a standardised drug dosage table avoided miscalculations and reported more confidence with prescriptions.⁸

In 2006, the WHO published simplified weight-band dosing tables on all ARV drugs for which there were available paediatric indications, formulations or sufficient information and evidence to provide guidance on prescribing and doses.⁹ Decisions about dosing were based upon manufacturers' information, ARV formulation choices, available data from clinical studies and expert paediatric pharmacology consultation. What was considered to be the 'optimal' dose for a particular weight band, given the limitations imposed by currently available drug formulations, was selected. Weight-band doses were determined by using BSA values calculated from median height-for-weight from international growth charts using the following formula: $BSA = \text{square root} [(weight (kg) \times height (cm))/3 600]$.

The dosing tables are directed at RLS and are based on the following principles:

1. It is preferable to use one formulation or fixed combination of any given drug(s).
2. Syringes or other standardised devices of various sizes should be available to support accurate dosing of liquid formulations.
3. Large volumes of liquid or syrup formulations should be avoided where possible.
4. In general, children should be switched to available solid formulations as soon as possible or as soon as they are tolerated.
5. If liquids or syrups are difficult because of storage, large volumes required or palatability, solid dosage formulations are preferable.
6. If solid formulations of first-line and second-line drugs developed for children are unavailable, solid formulations currently used for adults can be used.
7. Many tablets, but not all, may be divided in half but not beyond as drug content cannot be guaranteed. Scored tablets are more easily split. Some tablets cannot be split, and the WHO recommends that where possible tablet splitting be done in the dispensing pharmacy using appropriate tablet cutters.
8. Some adult FDCs may result in under-dosing of individual components in children. This is of con-

cern, particularly with drugs such as NNRTIs and 3TC where there is a low threshold for resistance. NVP requires a 'lead-in' dosage. During the first 2 weeks, therefore rather use individual components of the regimen.

9. Different dosing between a.m. and p.m. should be avoided where possible. However, in order to keep all regimens to no more than twice daily, there are instances where different quantities of solid dosage forms can be administered a.m. as opposed to p.m.
10. The doses in the tables are presented in weight bands, accepting that some deviation from target dosing will occur.
11. Children have to be weighed at each clinic visit, and dose changes are required as children grow and/or gain weight.
12. When capsules are opened or tablets dissolved or crushed and added to food or liquid, it is important that the entire volume/amount of vehicle be taken to ensure administration of the full dose.


The dosing tables are based on standardised weight bands starting from 5 kg body weight for the individual ARV drugs (excluding EFV, which starts from 10 kg) and 10 - 14 kg for the fixed-dose combinations (AZT + 3TC, d4T + 3TC, AZT + 3TC + ABC, d4T + 3TC + NVP). The weight bands are in 1 kg divisions from 5 to 11 kg, and 2 - 5 kg divisions from 12 to 35 or 40 kg.

ADAPTING WEIGHT-BAND DOSING TABLES FOR DIFFERENT SETTINGS

Dosing tables may be adapted according to the specific drug formulations available to a regional or national treatment programme. For example, dual (d4T + 3TC) or triple (d4T or AZT + 3TC + NVP) FDCs play an important role in paediatric ART in many countries (e.g. Thailand and many African countries), but are not widely used in South Africa. Satisfactory early clinical and immunological outcomes have been described following the use of fractions of generic adult FDCs in children dosed according to a weight-band table method in Thailand.¹⁰

In another project, a visual dosing aid (VDA) incorporating coloured dosing bands for five first-line ARV drugs was developed to assist clinicians in prescribing paediatric ART consisting of syrups, generic adult tablets or a combination. It compared well with generic paediatric FDC tablets and could help facilitate paediatric ART roll-out in RLS.¹¹

The South African national guidelines for the management of HIV-infected children (2005) incorporate a weight-band dosing chart^{12,13} developed by the Centers for Disease Control and Prevention (CDC) and a number of international paediatric AIDS programmes



prior to the more widespread availability of FDCs. BSA dosing recommendations were converted to weight-band doses using approximations of weight-for-age and height-for-age derived from standardised growth charts of girls from birth to 36 months and 20 years in the USA (National Center for Health Statistics). Dose for each weight band was based on the practicality of the available dosage forms for each drug, and practical storage and dosing instructions were included with the chart. The chart lacks dose recommendations for children weighing less than 5 - 7 kg and for HIV-TB co-infection.

The Western Cape Antiretroviral Drug Dosing Chart for Children (2007), based on the 2006 WHO recommendations, was developed by the author and colleagues as a pilot project for the HIV Directorate of the Western Cape (South Africa) provincial health department. The chart was directed at both clinicians and pharmacists involved in prescribing and dispensing ART for children, and it was successfully piloted at a number of HIV clinics before being distributed across the province. It was produced as a laminated A4 colour copy. Standard first- and second-line ART regimens (including regimens compatible with rifampicin-based TB treatment) as well as general comments relating to storage, administration and common drug interactions and side-effects of the individual ARV drugs were printed on the reverse side. Only ARV formulations available at public sector treatment facilities were included (no FDCs were available), and there was an emphasis on the early introduction of solid formulations where possible. Fractions of tablets (not less than half a tablet) were only incorporated for scored tablets. The target dose in mg/kg or mg/m² for each drug as well as the formula for calculating BSA was included to facilitate comparison of dosing methods when necessary.

The following local practices were incorporated:

1. The off-label 'opened capsule' d4T dosing method whereby a d4T capsule is opened and the powder contents dispersed in a standardised volume of water and the required dose drawn up with a syringe and administered to the child (e.g. to administer a standardised d4T dose of 10 mg for the weight bands 7 - 9.9 kg, a 20 mg d4T capsule is opened and dispersed into 5 ml of water and 2.5 ml is withdrawn with a syringe and administered and the remaining 2.5 ml is discarded). The rationale for this method is to minimise the use of stavudine solution (1 mg/ml when reconstituted), which is expensive, requires refrigeration, and results in relatively large medication volumes for administration to young infants at the usual dosing schedule (1 mg/kg/dose). There are now data based on high-performance liquid chromatography analysis of active drug concentration in dispersed capsule solutions, supporting the accuracy of this method

for certain brands of d4T capsules.¹⁴

2. Standardised doses of ritonavir used for pharmacological boosting of LPV/r (in order to achieve a ratio of 1:1) in children receiving concurrent LPV/r and rifampicin-based TB treatment.¹⁵
3. Colour coding of ARVs on the chart corresponding to colour coding methods used in the pharmacy for medication containers and syringes to assist parents and caregivers with correct dosing.
4. The chart incorporated co-trimoxazole and multivitamin syrup dosing according to weight bands.
5. Since there were no standard weight-band dosing recommendations for infants weighing <5 kg in the WHO document (2006), it was recommended that a clinician experienced in ARV prescribing be consulted for such cases.

VALIDATION OF WEIGHT-BAND DOSING TABLES

There are a number of approaches to validation of weight-band dosing. Direct methods include pharmacokinetic (Pk) studies and therapeutic drug monitoring. Indirect methods include comparison of weight-based with BSA doses, and safety and efficacy studies. Qualitative studies assessing the usefulness of a weight-band dosing table to prescribing clinicians and dispensing pharmacists should be undertaken.

Differing growth rates and the prevalence of malnutrition could have a significant impact on the accuracy of weight-band dosing of drugs that are usually dosed by BSA. A study comparing the calculated BSA dose range with WHO weight-band doses for AZT, ddI, NVP and LPV/r using actual heights and weights of 601 children at the time of ARV initiation was undertaken at a tertiary hospital in South Africa in 2007.¹⁶ The median age was 28 months (interquartile range 13 - 62), 49% of children weighed <10 kg, and 59% and 63% of children had weight-for-age and height-for-age z-scores ≤ -2 (moderate to severe underweight or stunting), respectively. Children with body weight <5 kg were excluded as weight-based dosing recommendations were unavailable for this category, and children <6 months of age were excluded as LPV/r BSA dosing recommendations are different in this age group. The BSA dose ranges used were AZT 180 - 240 mg/m², ddI 90 - 120 mg/m², NVP 160 - 200 mg/m², and L/r 230 - 300 mg/m².

Results are presented in Table I. The conclusion of this study was that the 2006 WHO simplified weight band-dosing method effectively avoided under-dosing children in relation to existing BSA dose recommendations for AZT, NVP and LPV/r suspensions. However, the authors noted that the risk of over-dosing is greater with weight-band recommendations for existing capsule or tablet formulations of these ARVs. Further studies are recommended for the WHO weight-band dosing method.

TABLE I. WEIGHT-BAND DOSE RELATIVE TO CALCULATED BODY SURFACE AREA DOSE RANGE

ARV drug, BSA dose range, formulations assessed	Weight-band dose relative to calculated BSA dose range (N=601 children) (using anthropometric data at time of starting ART)	
	Under-dosing (% of children)	Over-dosing (% of children)
AZT		
180 - 240 mg/m ²		
Oral solution (10 mg/ml)	2	0.5
Capsules (100 mg)	8.5	19
ddl		
90 - 120 mg/m ²		
Tablets (25, 50, 100 mg, chewable or dispersible in water)	0	87
NVP		
160 - 200 mg/m ²		
Oral suspension (10 mg/ml)	0	53
Tablets (200 mg)	0	61
Lopinavir/ritonavir		
230 - 300 mg/m ²		
Oral solution (80/20 mg/ml)	1.2	26
Capsules (133.3/33.3 mg soft)	0	38

A VDA to facilitate dosing calculations in response to children's growth and weight during ARV treatment developed by Callens *et al.*¹¹ was evaluated using anthropometric data from 55 children from the USA and 324 children from the Democratic Republic of Congo (DRC). In comparison with WHO-recommended dosing, the authors noted a relative dosing difference of $\geq 20\%$ in $<3\%$ of children for NVP, AZT and d4T but in 20% of children for 3TC, over-dosing being more frequent.¹¹

A detailed review of Pk studies and clinical outcome, safety and efficacy studies undertaken in children treated with individual or FDC ARV drugs dosed according to weight bands is beyond the scope of this article. There are no reported Pk or clinical studies directly comparing weight band with mg/kg or BSA dosing approaches.

CURRENT WEIGHT-BAND TABLES

In July 2008, the WHO published a revised weight-band dosing table for individual ARVs as well as dual and triple FDCs applicable to children ≥ 6 weeks of age, indicating the number of tablets or millilitres of solution to be administered twice daily by weight band from 3 kg to 34.9 kg (Fig. 1).¹⁷ The table focuses on ARVs used in first-line regimens and was developed by the WHO Paediatric Antiretroviral Working Group using the 2006 WHO treatment recommendations, target doses and weight bands as a benchmark and reviewing currently available published and unpublished data to assess dosing. Ddl is not included in the dosing table. Key supporting references are provided in the document.¹⁸ See Table II for target doses or dosing ranges.

A WHO generic tool was used to assess and evaluate the expected dose delivered of any product in relation to intended target doses. For all formulations, changes in the number of pills and switches from one formula-

tion to another occur at the same weight bands. There was an attempt to avoid dosing any single ARV component below 90% of the intended delivered dose and not more than 25% above the intended dose (or dose range for products with an established dose range). For NVP, the aim was to avoid dosing below 100% of the minimum of the dose range (150 mg/m²). Discrepancies between dose delivered and intended dose were justified based on available Pk data, consideration of toxicity, and threshold for development of HIV drug resistance. Higher dosing for children who would fall into the lower weight bands (under 3 years) was accepted for drugs with known increased metabolism or clearance in the young child (NVP, 3TC, d4T, abacavir, LPV/r).

In South Africa, the Antiretroviral Drug Dosing Chart (2009) is an update of the 2007 Western Cape version and incorporates elements of the WHO 2008 table; in particular, dosing recommendations for weight bands 3 - 3.9 kg and 4 - 4.9 kg (Fig. 2). Many of the formulations in the WHO table, in particular the FDCs, are not currently available to public sector treatment programmes in South Africa and so are excluded. The registration and availability of the paediatric strength heat-stable LPV/r tablet (Aluvia; 100 mg lopinavir/25 mg ritonavir) is still awaited, but it has been included. Local dosing practices described in the 2007 chart have been retained with modification, e.g. the d4T opened-capsule method is now used from 5 kg body weight. A comparative analysis of the revised weight band dosing in comparison with BSA dosing for AZT, NVP and L/r has been completed but not yet published. An analysis of the dose of LPV/r solution in mg/m² that revised WHO weight band dose recommendations would provide, using anthropometric data on 976 children initiating ART at median age of 11.2 months, indicated doses considerably in excess of 300/75 mg/m², particularly for children <6 months of age.¹⁹ A protocol for an infant Pk study using the revised WHO weight-band dosing

Drug	Strength of tab (mg) or liquid mg/ml	Number of tablets or ml by weight band (twice daily)													Strength of adult tab (mg)	Number of tablets by weight band (twice daily)	
		Children 6 weeks of age and above (0.75 BD is delivered as 1 tablet AM and 0.5 tablets PM and 1.5 BD is delivered as 2 tablets AM and 1 tablet PM)															
		3-3.9 kg	4-4.9 kg	5-5.9 kg	6-6.9 kg	7-7.9 kg	8-8.9 kg	9-9.9 kg	10-10.9 kg	11-11.9 kg	12-13.9 kg	14-16.9 kg	17-19.9 kg	20-24.9 kg			
AZT	60	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300	25-29.9 kg	30-34.9 kg
AZT (new annex E)	300; 10 mg/ml	6 ml	6 ml	6 ml	9 ml	9 ml	9 ml	9 ml	12 ml	12 ml	12 ml	0.5	0.5	0.75	300	1	1
AZT/3TC	60/30	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300/150	1	1
AZT/3TC/NVP	60/30/50	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300/150/200	1	1
ABC	60	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300	1	1
ABC (new annex E)	300; 20 mg/ml	3 ml	3 ml	3 ml	4 ml	4 ml	4 ml	4 ml	6 ml	6 ml	6 ml	0.5	0.5	0.75	300	1	1
ABC/3TC	60/30	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300/150	1	1
ABC/3TC/NVP	60/30/50	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300/150/200	1	1
ABC/AZT/3TC	60/60/30	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	300/300/150	1	1
3TC	30	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	150	1	1
3TC (new annex E)	150; 10 mg/ml	3 ml	3 ml	3 ml	4 ml	4 ml	4 ml	4 ml	6 ml	6 ml	6 ml	0.5	0.5	0.75	150	1	1
d4T	6	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	30	1	1
d4T (new annex E)	various; 1 mg/ml	6 ml	6 ml	6 ml	9 ml	9 ml	9 ml	9 ml	1x15 mg	1x15 mg	1x15 mg	1x20 mg	1x20 mg	1x20 mg	30	1	1
d4T/3TC	6/30	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	30/150	1	1
d4T/3TC/NVP	6/30/50	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	30/150/200	1	1
NVP	50	1	1	1	1.5	1.5	1.5	1.5	2	2	2	2.5	2.5	3	200	1	1
NVP (new annex E)	200; 10 mg/ml	5 ml	5 ml	5 ml	8 ml	8 ml	8 ml	8 ml	10 ml	10 ml	10 ml	0.75	0.75	0.75	200	1	1
Lopinavir/ritonavir	100/25	n/r	n/r	n/r	n/r	n/r	n/r	n/r	1.5	1.5	1.5	2	2	2.5	100/25* (paed)	3	3
Lop/rit (new annex E)	80/20 mg/ml	1 ml	1.5 ml	1.5 ml	1.5 ml	1.5 ml	1.5 ml	1.5 ml	2 ml	2 ml	2 ml	2.5 ml	2.5 ml	3 ml	80/20 mg/ml	3.5 ml	4 ml

* 3 tablets BD of 100/25 may be substituted with 2 tablets am and 1 tablet pm of 200/50

Note: higher doses of Lop/rit may be required when co-administered with enzyme-inducing drugs such as NVP, EFV; fosamprenavir, rifampicin.

Fig. 1. Paediatric antiretroviral dosing table, World Health Organization (2008).¹⁷

TABLE II. DOSING CONSIDERATIONS FOR INDIVIDUAL ANTIRETROVIRAL DRUGS INCLUDED IN THE REVISED WHO DOSING TABLE (2008) AND ADAPTED FOR THE ANTIRETROVIRAL DRUG DOSING CHART (2009)¹⁸

Drug	Target dosing range	Considerations
ABC	8 - 10 mg/kg/dose twice daily	Clearance in children <3 years old is increased, but recent data on once-daily dosing in children from 3 months of age suggest favourable Pk profile
AZT	180 - 240 mg/m ² /dose twice daily	Twice-daily dosing is acceptable and preferred Dosing at the upper end of the range is recommended for central nervous system HIV disease; dosing at the lower end may be preferred in settings where anaemia is prevalent
d4T	1 mg/kg/dose twice daily	Needed as a priority product despite well-recognised longer-term toxicities (lipodystrophy), as it is initially well tolerated, is safer to use in anaemia than AZT, and has lower laboratory monitoring requirements Avoid over-dosing wherever possible (noting recent revision to adult dosing recommendation to reduce dose) and especially for extended periods to minimise toxicity
ddl	<3 months of age: 50 mg/m ² /dose; >3 months: 120 mg/m ² /dose twice daily	Enteric-coated formulations are preferred over the buffered form Needs to be given 1 hour before or 2 hours after food Once-daily dosing accepted over 6 years of age
3TC	4 mg/kg/dose twice daily	Clearance in children <3 years old is increased, and minimal observed toxicity allows for higher dosing in younger children (up to 5 mg/kg/dose twice daily)
NVP	A BSA dose range of 150 - 200 mg/m ² /dose twice daily is used to generate weight-band dosing	Under-dosing must be avoided wherever possible owing to low barrier development of HIV drug resistance A reduced dose (150 - 200 mg/m ² /dose once daily) is recommended for the first 2 weeks when initiating NVP treatment regimens Young children require a higher NVP dose relative to the NRTI components than delivered in current adult FDCs
EFV	By weight band (15 - 18.75 mg/kg/dose solid formulation or 19.5 mg/kg/dose suspension, once daily)	Dosing not established for children <3 years Suspension is over 30% less bio-available than solid formulations
LPV/r	Approved dose is 230/75.5 mg/m ² /dose twice daily; 300/75 mg/m ² /dose is recommended in children <2 years of age, if taken with NNRTI, or for PI-experienced patients	Clearance in children <2 years is increased Actual exposure depends on metabolism and inter-patient variability, which is considerable Heat-stable paediatric formulation recently approved (awaiting registration in SA)
RTV	Co-formulated with lopinavir (L:r ratio 4:1) For patients receiving rifampicin, additional RTV dosed at 0.75 x L/r dose to achieve L:r ratio of 1:1	Needed for use as a pharmacological booster with PI-based treatment and for children receiving rifampicin-based antituberculosis therapy

table and incorporating safety and efficacy end-points has been developed.

CONCLUSION

The use of weight-band ARV dosing approaches, adapted in accordance with locally available formulations and treatment programme conditions, is a key component of simplifying paediatric ART for health care providers as well as children and their caregivers, and will contribute to expanding treatment coverage for HIV-infected infants and children.

REFERENCES

1. UNICEF, UNAIDS, WHO and UNFPA. *Children and AIDS: Third Stocktaking Report, 2008*. Geneva: UNICEF, 2009. <http://www.childinfo.org/files/StocktakingReport08.pdf> (accessed 29 September 2009).
2. Violaro A, Cotton M, Gibb D, et al. Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med* 2008; 359: 2233-2244.
3. World Health Organization. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting WHO Headquarters, Geneva, Switzerland, 10 - 11 April 2008. http://www.who.int/hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_mreport_2008.pdf (accessed 8 October 2009).
4. Sohn A, Ananworanich J. How can we simplify antiretroviral therapy in children? *Curr Opin HIV AIDS* 2007; 2: 426-430.

Acknowledgements

For assistance with the development, analysis and implementation of the Western Cape Antiretroviral Drug Dosing Chart (2007): Shenaaz Raiman (pharmacist), Heather Jaspan, Brian Eley, Mary-Ann Davies, Brenda Smuts, David Pienaar, Heli Moeng, staff at the HIV clinic at Red Cross War Memorial Children's Hospital, Cape Town and Nolungile HIV clinic, Khayelitsha.

5. Package insert for Abbott Kaletra®, Abbott Laboratories, June 2005.
6. Mosteller RD. Simplified calculation of body-surface area. *N Engl J Med* 1987; 317: 1098.
7. Menson E, Walker A, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. *BMJ* 2006; 332: 1183-1187.
8. Ponnet M, Frederix K, Petdachai W, et al. A drug dosage table is a useful tool to facilitate prescriptions of antiretroviral drugs for children in Thailand. *Int J STD AIDS* 2005; 16: 420-426.
9. World Health Organisation. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, towards universal access: Recommendations for a public health approach. 2006. <http://www.who.int/hiv/pub/guidelines/en/> (accessed 8 October 2009).
10. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination

Target dose	Stavudine (d4T)	Lamivudine (3TC)	Zidovudine (AZT)	Didanosine (ddI)	Abacavir (ABC)	Efavirenz (EFV)	Nevirapine (NVP)	Lopinavir/ritonavir (LPV/r)	Ritonavir boosting (RTV)	Co-trimoxazole	Multi-vitamins	Target dose
Available formulations	Sol. 1mg/ml Caps 15,20,30mg	Sol. 10mg/ml Tabs 150mg (scored)	Sol. 10mg/ml Caps 100mg Tabs 300mg (not scored)	Tabs 25,50,100mg (dispersible in 30ml water) Caps 250mg EC (not scored)	Sol. 20mg/ml Tabs 300mg (not scored)	Caps 50, 200mg Tabs 50, 200, 600mg (not scored)	Sol. 10mg/ml Tabs 200mg (scored)	Sol. 80/200mg/ml Tabs 200/50mg, 100/25mg	Sol. 80mg/ml	Sol. 40/200mg/5ml Tabs 80/400mg (scored)	Sol. Tabs (B Co)	Available formulations
Wt. (kg)	Consult with a clinician experienced in paediatric ARV prescribing for neonates (<28 days of age) and infants weighing <3kg											
<3	6ml	3ml	6ml	avoid	3ml	Dosing <10kg not established	5ml	1ml	**1ml	2.5ml	2.5ml	<3
3-3.9								1.5ml	**1.2ml			3-3.9
4-4.9												4-4.9
5-5.9	7.5mg: open 15mg capsule into 5ml water: give 2.5ml & discard rest	4ml	9ml	2x25mg tabs	4ml		8ml			5ml OR ½ tab		5-5.9
6-6.9	10mg: open 20mg capsule into 5ml water: give 2.5ml & discard rest			1x50mg+ 1x25mg tabs								6-6.9
7-7.9	15mg: open 15mg capsule into 5ml water	6ml	12ml	1x50mg+ 1x25mg tabs am; 2x25mg tabs pm; 1x50mg+ 1x25mg tabs	6ml	200mg cap/tab	10ml	2ml twice daily OR 100/25mg tabs: 2 tabs am, 1 tab pm	**1.5ml		5ml	7-7.9
8-8.9												8-8.9
9-9.9												9-9.9
10-10.9												10-10.9
11-11.9												11-11.9
12-13.9												12-13.9
14-16.9	20mg: open 20mg capsule into 5ml water	½ tab	2 caps am; 1 cap pm	2x50mg tabs am; 1x50mg+ 1x25mg tabs pm	7ml	200mg cap/tab + 50mg cap/tab	1 tab am; ½ tab pm	2.5ml twice daily OR 100/25mg tabs: 2 tabs twice daily	**2ml	10ml OR 1 tab		14-16.9
17-19.9				2x30mg tabs	8ml							17-19.9
20-24.9	20mg am; 30mg pm	1 tab am; 1/2 tab pm	2 caps	1x100mg tab+ 1x25mg tab twice daily OR 1x250mg EC cap once daily	10ml	200mg cap/tab + 2x50mg caps/tabs		3ml twice daily OR 100/25mg tabs: 3 tabs am, 2 tabs pm	**2.5ml			20-24.9
25-29.9	30mg	1 tab	1 tab		1 tab	200mg cap/tab + 3x50mg caps/tabs; 2x200mg caps/tabs	1 tab	3.5ml twice daily OR 200/50mg tabs: 2 tabs am, 1 tab pm	**3ml			25-29.9
30-34.9								4ml twice daily OR 200/50mg tabs: 2 tabs am, 1 tab pm				30-34.9
35-39.9								5ml twice daily OR 200/50mg tabs: 2 tabs twice daily	**4ml	2 tabs	1 tab	35-39.9
>40						600mg tab						>40

* A lead-in dose of nevirapine is given for the first 14 days of treatment equivalent to half of maintenance dose i.e. usual maintenance dose but given once-daily. Increase to full maintenance dose after 14 days if no rash develops.

Compiled by J. Nuttall & S. Reiman for the Paediatric HIV/TB Policy Reference Group, Western Cape. Adapted from World Health Organisation guidelines, 2006 & 2008.

NEED HELP?
CALL NATIONAL HIV HCW HOTLINE
0800 212 506/021 406 6782
OR
send an sms or "please call me" message to
071 840 1572



Body Surface Area (BSA) $m^2 = \frac{\text{Mass (kg)} \times \text{Height (cm)}}{3600}$

Fig. 2. Antiretroviral drug dosing chart for children (2009) (copies available via National HIV Health Care Worker Hotline 0800 212 506).

antiretroviral therapy. *AIDS* 2006; 20: 1955-1960.

11. Callens SF, Westreich D, Kitetele F, et al. A visual dosing aid for first-line pediatric antiretroviral treatment in resource-poor settings. *J Trop Pediatr* 2008; 55: 135-137.
12. National Department of Health, South Africa. *Guidelines for the Management of HIV-infected Children*. 1st ed. National Department of Health, South Africa, 2005.
13. Weidle PJ, Abrams EJ, Gvetadze R, Rivadeneira E, Kline MW. A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. *Pediatr Infect Dis J* 2006; 25: 59-64.
14. Innes S, Smuts M, Cotton M, Seifart H, Rosenkranz B. Comparative study of different brands of stavudine capsules for the off-label 'opened capsule' method recommended for HIV-infected infants and children in resource-limited settings. *South African Journal of Child Health* 2009; 3: 44-47.
15. Ren Y, Nuttall J, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. *J Acquir Immune Defic Syndr* 2008; 47: 566-569.
16. Nuttall J, Eley B, Davies M. Comparison of body surface area-based dosing and a simplified weight-based dosing method for zidovudine, didanosine, nevirapine and lopinavir/ritonavir in children starting antiretroviral therapy. Paper presented at the 3rd South African AIDS Conference, 5 - 8 June 2007, Durban (Abstract 538).
17. World Health Organization. Annex E: Simplified weight based Paediatric dosing for antiretroviral medicines <http://www.who.int/hiv/topics/paediatric/technical/en/index.html> (accessed 17 November 2009).
18. World Health Organization. Report of the WHO expert working group meeting to determine preferred ARV medicines for treating and preventing HIV infection in younger children, 2008 <http://www.who.int/hiv/topics/paediatric/technical/en/index.html> (accessed 17 November 2009).
19. Nuttall J, Eley B, Davies M-A. How well do the revised World Health Organization weight-based dosing guidelines for lopinavir/ritonavir in infants and children correlate with body surface area-based dosing recommendations? Paper presented at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 19 - 22 July 2009, Cape Town (Abstract MOAB105).

